MA52973B1 - Formes solides du sel de tartrate de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, procédé pour leur préparation et méthodes de leur utilisation pour le traitement de cancers - Google Patents

Formes solides du sel de tartrate de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, procédé pour leur préparation et méthodes de leur utilisation pour le traitement de cancers

Info

Publication number
MA52973B1
MA52973B1 MA52973A MA52973A MA52973B1 MA 52973 B1 MA52973 B1 MA 52973B1 MA 52973 A MA52973 A MA 52973A MA 52973 A MA52973 A MA 52973A MA 52973 B1 MA52973 B1 MA 52973B1
Authority
MA
Morocco
Prior art keywords
methods
difluoropropan
fluoropropyl
azetidin
pyrido
Prior art date
Application number
MA52973A
Other languages
English (en)
Other versions
MA52973A (fr
Inventor
Francis Gosselin
Paroma Chakravarty
Hans Iding
Haiming Zhang
Jie Xu
Cheol Keun Chung
Kyle Clagg
Michael Dalziel
Alec Fettes
Ngiap-Kie Lim
Andrew Mcclory
Kartik Nagapudi
Sarah Robinson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority claimed from PCT/US2019/037492 external-priority patent/WO2019245974A1/fr
Publication of MA52973A publication Critical patent/MA52973A/fr
Publication of MA52973B1 publication Critical patent/MA52973B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des formes solides, des sels tels que le composé b et des formulations de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, des procédés et la synthèse de ceux-ci et des méthodes d'utilisation de ceux-ci dans le traitement d'un cancer.
MA52973A 2018-06-21 2019-06-17 Formes solides du sel de tartrate de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, procédé pour leur préparation et méthodes de leur utilisation pour le traitement de cancers MA52973B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687930P 2018-06-21 2018-06-21
PCT/US2019/037492 WO2019245974A1 (fr) 2018-06-21 2019-06-17 Formes solides de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol et procédés pour la préparation de composés tricycliques condensés comprenant une fraction phényle ou pyridinyle substituée et leurs méthodes d'utilisation

Publications (2)

Publication Number Publication Date
MA52973A MA52973A (fr) 2021-04-28
MA52973B1 true MA52973B1 (fr) 2023-08-31

Family

ID=73543352

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52973A MA52973B1 (fr) 2018-06-21 2019-06-17 Formes solides du sel de tartrate de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, procédé pour leur préparation et méthodes de leur utilisation pour le traitement de cancers

Country Status (2)

Country Link
AR (1) AR114974A1 (fr)
MA (1) MA52973B1 (fr)

Also Published As

Publication number Publication date
MA52973A (fr) 2021-04-28
AR114974A1 (es) 2020-11-11

Similar Documents

Publication Publication Date Title
RU2471781C2 (ru) Новые двузамещенные фенилпирролидины в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии
MX2023006785A (es) Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3- il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[ 3,4-b]indol-2-il)-2,2- difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso.
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA46038B1 (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA38227B1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
JP2009530282A5 (fr)
EA201791941A1 (ru) Бициклические кетосульфонамидные соединения
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA34308B1 (fr) Triazolopyridines substituées
MA38260B1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA44079B1 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA39186A1 (fr) Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose
SA520420382B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1